Loading...
XHKG
6821
Market cap7.91bUSD
Jul 09, Last price  
115.30HKD
1D
5.30%
1Q
19.11%
IPO
-56.37%
Name

Asymchem Laboratories Tianjin Co Ltd

Chart & Performance

D1W1MN
XHKG:6821 chart
P/E
29.35
P/S
4.98
EPS
3.40
Div Yield, %
1.71%
Shrs. gr., 5y
1.78%
Rev. gr., 5y
16.29%
Revenues
6.67b
+14.91%
405,691,300424,399,200542,757,600716,207,200830,607,6941,103,194,9511,423,033,4121,834,877,6232,459,985,5333,136,724,0004,632,121,00010,230,186,0007,825,190,2975,804,657,3366,670,181,013
Net income
1.13b
+19.35%
65,372,50060,251,40074,729,500101,791,600153,545,029252,735,205341,287,662428,295,479553,863,843719,742,0001,069,273,9993,301,635,0002,268,810,446948,950,0381,132,569,775
CFO
1.41b
+12.22%
25,883,50034,384,900105,917,363127,045,751256,994,132278,355,646196,400,310415,060,930600,867,843569,291,589113,150,1213,286,910,7053,549,728,3831,254,337,0141,407,585,059
Dividend
Jun 13, 20241.9767 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Asymchem Laboratories (Tianjin) Co., Ltd. functions as a contract development and manufacturing organization (CDMO), offering its expertise to pharmaceutical and biotechnology companies both globally and within Mainland China. Their services encompass drug research, development, and production, supporting projects across the entire drug lifecycle, from early clinical phases to commercial scale. This includes R&D and cGMP-compliant manufacturing of advanced intermediates, active pharmaceutical ingredients (APIs), and finished drug formulations, in addition to providing clinical research support. Furthermore, Asymchem engages in pharmaceutical analysis and testing, the distribution (wholesale, retail, and direct sale) of medicines, and initiatives focused on advancing pharmaceutical science and technology. The company, established in 1999, maintains its headquarters in Tianjin, China.
URL
https://www.asymchem.com.cn/
IPO date
Nov 18, 2016
Employees
9,719
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT